IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines

J Interferon Cytokine Res. 2004 Apr;24(4):231-43. doi: 10.1089/107999004323034105.

Abstract

Various human colon cancer cell lines tested in vitro differed significantly in susceptibility to growth inhibition of recombinant human interferon-beta (rHuIFN-beta). Two p53-mutant lines, COH and CC-M2, derived from high-grade colon adenocarcinoma, showed signs of apoptosis after treatment with 250 IU/ml of HuIFN- beta in the culture medium. The similarly p53-mutated HT-29 line from a grade I adenocarcinoma showed no apoptosis, however, and only cell cycle G1/G0 or S phase retardation with 1000 IU/ml HuIFN-beta. After HuIFN-beta exposure, COH and CC-M2 cells showed increased levels of Fas and FasL proteins, alteration of mitochondrial membrane potential, and activation of caspase-9, caspase-8, and caspase-3 in a time-dependent manner. Treatment of COH and CC-M2 cells with anti-FasL antibodies or rFas/Fc fusion protein, however, could not prevent the apoptosis induced by HuIFN-beta. In contrast, cell-permeable specific inhibitors of the three caspases could inhibit the DNA fragmentation and cell death but not the mitochondrial membrane potential changes. Treatment with mitochondria-stabilizing reagents could significantly abrogate the apoptosis and caspase activation induced by HuIFN-beta. These results suggest that in COH and CC-M2 colon cancer cell lines, HuIFN-beta induces apoptosis mainly through mitochondrial membrane alteration and subsequent activation of the caspase cascade pathway, but not by the Fas/FasL interaction or the p53-dependent apoptotic mechanism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / enzymology
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity
  • Apoptosis / drug effects*
  • Caspase Inhibitors
  • Caspases / metabolism*
  • Cell Line, Tumor
  • Colonic Neoplasms / enzymology*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology*
  • Cytochromes c / metabolism
  • Enzyme Activation / drug effects
  • Fas Ligand Protein
  • Genes, p53 / genetics
  • Humans
  • Interferon Type I / pharmacology*
  • Interferon Type I / toxicity
  • Membrane Glycoproteins / metabolism
  • Membrane Potentials / drug effects
  • Mitochondria / drug effects*
  • Mitochondria / enzymology
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Mutation / genetics
  • Proteins / metabolism
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2*
  • Receptors, Tumor Necrosis Factor*
  • Recombinant Proteins
  • bcl-2-Associated X Protein
  • fas Receptor

Substances

  • Antineoplastic Agents
  • Caspase Inhibitors
  • FAS protein, human
  • FASLG protein, human
  • Fas Ligand Protein
  • Interferon Type I
  • Membrane Glycoproteins
  • Proteins
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Tumor Necrosis Factor
  • Recombinant Proteins
  • bcl-2-Associated X Protein
  • fas Receptor
  • Cytochromes c
  • Caspases